It’s imperative that pharmaceutical companies maintain their commitment to safety even after therapies are discontinued. It is equally important that clinical trial and commercial data on all gene therapy products continue to be collected over the long-term to monitor safety outcomes.
The position of the WFH and other organizations has been outlined in two previously published articles:
- “Critical Juncture in the Development of Hemophilia Therapies A Statement and Call-to-Action from the International Society on Thrombosis and Haemostasis (ISTH) European Association for Haemophilia and Allied Disorders (EAHAD) World Federation of Hemophilia (WFH) for the importance of continued research into and development of effective and safe hemophilia treatments” which can be read here
- “The Critical Need to Consolidate All Gene Therapy Data in Haemophilia” which was published in Haemophilia and which can be read here
The WFH urges all pharmaceutical companies involved in hemophilia treatment products to maintain their commitments to our global community. Data can be collected through the WFH Gene Therapy Registry (GTR), a prospective, observational, and longitudinal registry designed to collect long-term data on people with hemophilia (PWH) who receive gene therapy. To find out more about the registry, click here.










